<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00697983</url>
  </required_header>
  <id_info>
    <org_study_id>MEC 08-3-029</org_study_id>
    <secondary_id>EU FP7, grant no. 202231</secondary_id>
    <nct_id>NCT00697983</nct_id>
  </id_info>
  <brief_title>Cohort Study on Associations Between Purinergic Receptor SNPs and Osteoporosis Risk</brief_title>
  <acronym>ATPBone</acronym>
  <official_title>Purinergic Signalling in Human Osteoporosis: Evaluation of Variability in Purinergic Receptor Genes and Receptor Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Copenhagen University Hospital, Research Center for Aging and Osteoporosis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Osteoporosis is a high-prevalence disease with a strong genetic component.
      Nucleotides, including ATP (adenosine 5'-triphosphate) and its purinergic receptors, play a
      role in bone physiology. Single nucleotide polymorphisms (SNPs) in the P2X7 receptor gene
      were recently found to be associated with fracture risk in a cohort of postmenopausal women.

      Objective: To investigate associations between purinergic receptor SNPs and osteoporosis risk
      in humans. Genetic data from a fracture cohort in the Netherlands with high prevalence of
      osteoporosis will be analyzed. Furthermore, effects of aberrant purinergic receptor
      signalling on bone turnover markers will be assessed ex vivo.

      Design: The cohort will include app. 1,000 fracture patients of 50 years and older, who will
      be recruited at the Maastricht University Medical Center during standard medical follow-up
      after a clinical fracture. The standard medical follow-up includes assessment of bone mineral
      density (BMD) by Dual-Energy X-ray Absorptiometry (DXA), if necessary followed by medication
      for osteoporosis. Prior to medication, blood samples will be collected from fracture patients
      to be genotyped for purinergic receptor SNPs and analyzed for biochemical markers of bone
      turnover. Systemic correlates of osteoporosis will be compared between osteoporotic subjects
      (i.e. low BMD) and non-osteoporotic controls (i.e. normal to high BMD). Subsequently, whole
      blood assays in patient subgroups (n=20 per subgroup), based on BMD and purinergic receptor
      SNPs, will be performed to evaluate ex vivo effects of ATP and related nucleotides bone
      markers.

      Study population: Patients of 50 years and older attending an outpatient osteoporosis clinic
      at the Maastricht University Medical Center for standard medical follow-up after a clinical,
      non-pathological fracture.

      Primary outcome parameters: BMD and purinergic receptor SNPs.

      Secondary outcome parameters: Bone markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Purinergic receptor SNPs</measure>
    <time_frame>cross-sectional</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BMD</measure>
    <time_frame>cross-sectional</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biochemical markers of bone turnover</measure>
    <time_frame>cross-sectional</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Fracture cohort</arm_group_label>
    <description>Patients of 50 years and above with a clinical, non-pathological fracture, who attend an osteoporosis outpatient clinic at the Maastricht University Medical Center for standard medical care (including bone densitometry by DXA-scan).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Fracture patients of 50 years and older attending an osteoporosis outpatient clinic at the
        Maastricht University Medical Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 50 years and older;

          -  Clinical fracture;

          -  Attending osteoporosis outpatient clinic for standard medical care.

        Exclusion Criteria:

          -  Disease of bone metabolism (e.g. bone tumours, hyperparathyroidism);

          -  Unwillingness to donate blood for DNA analyses;

          -  Failure of bone densitometry (DXA-scan).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter C Dagnelie, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University, Dept of Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.atpbone.org</url>
    <description>European Nucleotides and Bone Consortium</description>
  </link>
  <link>
    <url>http://ec.europa.eu/research/fp7/index_en.cfm</url>
    <description>European Commission Research, Seventh Framework Programme</description>
  </link>
  <link>
    <url>http://www.azm.nl</url>
    <description>University Hospital Maastricht</description>
  </link>
  <reference>
    <citation>van Helden S, van Geel AC, Geusens PP, Kessels A, Nieuwenhuijzen Kruseman AC, Brink PR. Bone and fall-related fracture risks in women and men with a recent clinical fracture. J Bone Joint Surg Am. 2008 Feb;90(2):241-8. doi: 10.2106/JBJS.G.00150.</citation>
    <PMID>18245581</PMID>
  </reference>
  <reference>
    <citation>Ohlendorff SD, Tofteng CL, Jensen JE, Petersen S, Civitelli R, Fenger M, Abrahamsen B, Hermann AP, Eiken P, Jørgensen NR. Single nucleotide polymorphisms in the P2X7 gene are associated to fracture risk and to effect of estrogen treatment. Pharmacogenet Genomics. 2007 Jul;17(7):555-67. Erratum in: Pharmacogenet Genomics. 2007 Sep;17(9):787. Jrgensen, Niklas R [corrected to Jørgensen, Niklas R].</citation>
    <PMID>17558311</PMID>
  </reference>
  <reference>
    <citation>Hoebertz A, Arnett TR, Burnstock G. Regulation of bone resorption and formation by purines and pyrimidines. Trends Pharmacol Sci. 2003 Jun;24(6):290-7. Review.</citation>
    <PMID>12823955</PMID>
  </reference>
  <reference>
    <citation>Bours MJ, Swennen EL, Di Virgilio F, Cronstein BN, Dagnelie PC. Adenosine 5'-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. Pharmacol Ther. 2006 Nov;112(2):358-404. Epub 2006 Jun 19. Review.</citation>
    <PMID>16784779</PMID>
  </reference>
  <reference>
    <citation>Swennen EL, Bast A, Dagnelie PC. Purinergic receptors involved in the immunomodulatory effects of ATP in human blood. Biochem Biophys Res Commun. 2006 Sep 29;348(3):1194-9. Epub 2006 Aug 4.</citation>
    <PMID>16904065</PMID>
  </reference>
  <reference>
    <citation>Bours MJL, Wesselius A en Dagnelie PC. Adenosinetrifosfaat (ATP), purinerge receptoren en botremodellering. Nieuwe perspectieven voor behandeling van osteoporose? Ned Tijdschr Calcium Botstofwisseling 2009; 7(3):71-4.</citation>
  </reference>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 11, 2008</study_first_submitted>
  <study_first_submitted_qc>June 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2008</study_first_posted>
  <last_update_submitted>April 19, 2011</last_update_submitted>
  <last_update_submitted_qc>April 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2011</last_update_posted>
  <responsible_party>
    <name_title>dr. ir. P.C. Dagnelie</name_title>
    <organization>Maastricht University Medical Center</organization>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>ATP</keyword>
  <keyword>Purinergic receptors</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Single nucleotide polymorphism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

